Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421650 | 0.82 | GRM5 (0.47) | GRM5 | |
| SCHEMBL200313 | 0.82 | TTR (0.52) | MEN1TTRALBKMT2APGR | |
| SCHEMBL56741 | 0.82 | GRM5 (0.43) | MEN1TTRALBKMT2AGRM5 | |
| SCHEMBL504640 | 0.82 | TTR (0.52) | MEN1TTRALBKMT2APGR | |
| SCHEMBL27574747 | 0.76 | CHRNB4 (0.32) | — | |
| SCHEMBL4456497 | 0.76 | GRM5 (0.42) | GRM5 | |
| SCHEMBL13606452 | 0.75 | GRM5 (0.53) | GRM5PGR | |
| SCHEMBL4457929 | 0.75 | GRM5 (0.56) | GRM5 | |
| SCHEMBL22202971 | 0.74 | CHRNB4 (0.31) | GRM5 | |
| SCHEMBL16950941 | 0.73 | TTR (0.44) | MEN1TTRALBKMT2APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-4739669-A1 | SODIUM CHANNEL BLOCKERS | Novartis AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-3887359-B1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | UNIV COPENHAGEN (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-28 | — | — | US | disclosed |
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | CTRL, PTMS, DDT | MEN1 4381/4885TTR 1446/4885ALB 2123/4885 |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | MEN1 349/4885TTR 4031/4885ALB 4664/4885 |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | MEN1 1555/4885TTR 3982/4885ALB 4493/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | MEN1 2848/4885TTR 3135/4885ALB 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.